Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739654) titled 'Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma' on July 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: King Edward Medical University

Condition: DLBCL - Diffuse Large B Cell Lymphoma

Intervention: Drug: Cisplatin

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: March 18, 2026

Target Sample Size: 74

Countries of Recruitment: Pakistan

To know more, visit https://clinicaltrials.gov/study/NCT07739654

Disclai...